套住了 止损查看全文
牛唐2020-06-19 14:01
生物医药领域成为疫情期间IPO的亮点,在过去两个月里,包括$Lyra Therapeutics(LYRA)$ 在内,有4家上市公司都属于生物医药的范畴,包括$ORIC制药(ORIC)$ ,$Keros(KROS)$ ,以及Zentalis Pharmaceuticals。这些生物医药公司不仅顺利IPO,而且平均回报率达82%查看全文
$Lyra Therapeutics(LYRA)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001567619-23-006334 Act: 33 Size: 17 KB 网页链接
$Lyra Therapeutics(LYRA)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-23-164470 Act: 34 Size: 154 KB 网页链接
$Lyra Therapeutics(LYRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-23-014352 Size: 28 KB 网页链接
$Lyra Therapeutics(LYRA)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001193125-23-159856 Act: 34 Size: 80 KB 网页链接
$Lyra Therapeutics(LYRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-23-012744 Size: 14 KB 网页链接
$Lyra Therapeutics(LYRA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-23-014350 Size: 18 KB 网页链接
$Lyra Therapeutics(LYRA)$ 8-K Current report, items 1.01, 3.02, 8.01, and 9.01 Accession Number: 0001193125-23-157998 Act: 34 Size: 1 MB 网页链接
$Lyra Therapeutics(LYRA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-23-021497 Act: 34 Size: 7 MB 网页链接
$Lyra Therapeutics(LYRA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-23-021491 Act: 34 Size: 455 KB 网页链接
$Lyra Therapeutics(LYRA)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-23-014432 Act: 34 Size: 1 MB 网页链接